close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

2.085 -0.065 (-3.02%)
Delayed Quote Updated: 9:40 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Top movers in Thursday's session ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Longeveron Inc. (NASDAQ:LGVN) Reports Q4 2025 Earnings Beat and Updates Lomecel-B Timeline ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Longeveron ↗
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
News headline image
Longeveron (LGVN) Q2 2026 Earnings Call Transcript ↗
ELPIS II trial data expected September 2026 as cash runway extends into Q4. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Longeveron (LGVN) Q1 2026 Earnings Transcript ↗
Longeveron (LGVN) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
News headline image
Longeveron (LGVN) Q4 2025 Earnings Call Transcript ↗
Longeveron (LGVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
Which stocks are moving on Tuesday? ↗
Via Chartmill
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study ↗
Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks have an unusual volume in today's session ↗
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
News headline image
Longeveron Posts 32% Revenue Drop in Q2 ↗
Via The Motley Fool
News headline image
Longeveron Inc. (NASDAQ:LGVN) Q2 2025 Earnings: Revenue Misses, EPS Narrower Than Expected ↗
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's... 
Via Chartmill
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.